Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.

The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.

RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx, Inc.

Country	United States
Founded	2012
IPO Date	Aug 26, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Shaun Bagai

Contact Details

Address: 4546 El Camino Real, Suite B1 Los Altos, California 94022 United States
Phone	650 284 4433
Website	renovorx.com

Stock Details

Ticker Symbol	RNXT
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$9.00
CIK Code	0001574094
CUSIP Number	75989R107
ISIN Number	US75989R1077
Employer ID	27-1448452
SIC Code	2834

Key Executives

Name	Position
Shaun R. Bagai	Chief Executive Officer, Secretary and Director
Dr. Ramtin Agah M.D.	Founder, Chairman of Board and Chief Medical Officer
Ronald B. Kocak CPA, CGMA	Vice President, Controller and Principal Accounting Officer
Leesa Gentry	Chief Clinical Officer
Ryan Witt	Senior Vice President and Head of Corporate Strategy and Partnerships

Latest SEC Filings

Date	Type	Title
Nov 14, 2024	8-K	Current Report
Nov 13, 2024	10-Q	Quarterly Report
Sep 25, 2024	8-K	Current Report
Aug 16, 2024	8-K	Current Report
Aug 13, 2024	10-Q	Quarterly Report
Jun 7, 2024	8-K	Current Report
May 10, 2024	EFFECT	Notice of Effectiveness
May 10, 2024	EFFECT	Notice of Effectiveness
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	424B3	Prospectus

View All SEC Filings